Article info
PDFOriginal article
Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study
- Correspondence to Line Jee Hartmann Rasmussen, Clinical Research Centre 056, Copenhagen University Hospital Hvidovre, Kettegaard Allé 30, Hvidovre, Copenhagen DK-2650, Denmark; line.jee.hartmann.rasmussen{at}regionh.dk
Citation
Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study
Publication history
- Received October 5, 2015
- Accepted July 26, 2016
- First published September 2, 2016.
Online issue publication
October 20, 2016
Article Versions
- Previous version (20 October 2016).
- You are viewing the most recent version of this article.
Abstract in Danish
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Abstract in Danish - Online abstract
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/